Scarica l'app Stockscreener
33.69
1.94%
0.64
Pre-mercato:
34.56
0.87
+2.58%
Precedente Chiudi:
$33.05
Aprire:
$33.3
Volume 24 ore:
96,060
Relative Volume:
0.96
Capitalizzazione di mercato:
$2.22B
Reddito:
$282.04M
Utile/perdita netta:
$221.88M
Rapporto P/E:
10.01
EPS:
3.3658
Flusso di cassa netto:
$-449.57M
1 W Prestazione:
-0.97%
1M Prestazione:
-2.71%
6M Prestazione:
+5.58%
1 anno Prestazione:
+30.94%
Intervallo 1D:
$33.04
$33.84
Intervallo di 1 settimana:
$32.45
$34.16
Portata 52W:
$22.59
$37.78
Galapagos Nv Adr Stock (GLPG) Company Profile
Nome
Galapagos Nv Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare GLPG vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
33.69 | 2.18B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2025-02-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-11-20 | Downgrade | Kepler | Hold → Reduce |
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-03-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-08-24 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-11-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-08-06 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-04-20 | Iniziato | Deutsche Bank | Buy |
| 2021-04-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-02-19 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | Iniziato | Maxim Group | Buy |
| 2020-10-21 | Downgrade | Goldman | Neutral → Sell |
| 2020-08-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-08-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-08-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-07-10 | Downgrade | Stifel | Buy → Hold |
| 2020-03-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-18 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-18 | Downgrade | Citigroup | Buy → Neutral |
| 2019-12-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | Iniziato | BofA/Merrill | Neutral |
| 2019-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2019-07-31 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-29 | Downgrade | Jefferies | Buy → Hold |
Mostra tutto
Galapagos Nv Adr Borsa (GLPG) Ultime notizie
Galapagos FY 2025 slides: €3B cash fuels transformation strategy - Investing.com Australia
RBC Capital raises Galapagos stock price target to $33 on model updates - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises By Investing.com - Investing.com South Africa
Galapagos stock rating reiterated at Market Perform by Raymond James - Investing.com
Galapagos FY 2025 slides: €3B cash fuels transformation strategy By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises - Investing.com
Earnings Breakdown: Galapagos Q4 - Sahm
A Peek at Galapagos's Future Earnings - Sahm
Stock Market Today: Nasdaq Futures Pare Losses, Dow Drops After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus (UPDATED) - Benzinga
Stock Market Today: Nasdaq Futures Pare Losses, Dow Drops After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones Futures Drop After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus - Sahm
AngioDynamics, Microchip Technology And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Galapagos NV (NASDAQ:GLPG) Given Average Rating of “Reduce” by Analysts - Defense World
Galapagos stock holds steady as Raymond James maintains Market Perform rating By Investing.com - Investing.com South Africa
Galapagos stock holds steady as Raymond James maintains Market Perform rating - Investing.com
Bernstein initiates Market Perform rating on Galapagos stock with EUR27.90 target - Investing.com
Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus
Operating cash flow per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Working capital per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Galapagos NV (NASDAQ:GLPG) Receives Average Rating of “Reduce” from Analysts - Defense World
EBIT per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady By Investing.com - Investing.com Canada
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady - Investing.com
Galapagos stock price target raised to $28 from $27 at RBC Capital - Investing.com
Galapagos stock rating upgraded by Leerink Partners on cost-cutting moves - Investing.com
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos Appoints Fred Blakeslee as General Counsel - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN) - The Globe and Mail
How Have Insiders Been Trading Winmark Corporation (WINA) Stock? - fostersleader.com
Why You Need Galapagos NV ADR (GLPG) On Your Watchlist - fostersleader.com
Stock on Demand This Week: Hour Loop Inc (HOUR) - fostersleader.com
MasterCraft Boat Holdings Inc (MCFT): What the Financials Tell Us - fostersleader.com
Is Buying Stock In Radiopharm Theranostics Ltd ADR (RADX) A Good Move Today? - fostersleader.com
Major Brokerage Firms Issue Research Notes on Surgepays Inc (SURG) - fostersleader.com
Vishay Precision Group Inc (VPG) Shares: Cheap or Risky? - fostersleader.com
Clene Inc (CLNN): What Technical Indicators Show - fostersleader.com
SolarMax Technology Inc (SMXT): What Does Valuation Ratios Tell Us? - fostersleader.com
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - TechStock²
Galapagos Updates on Cell Therapy Business Strategic Review - The Globe and Mail
Galapagos NV (GLPG)' CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial - Finviz
Galapagos (0JXZ) was downgraded to a Sell Rating at Deutsche Bank - The Globe and Mail
Galapagos NV Reports Strong H1 2025 Results Amid Strategic Transformation - The Globe and Mail
Raymond James reiterates Market Perform rating on Galapagos stock - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com
Galapagos stock holds as CEO change, spinoff plans halted - Investing.com
Galapagos stock holds Market Perform rating at Raymond James - Investing.com
Galapagos To Spin Off Innovative Medicines Business - Forbes
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com
Galapagos Nv Adr Azioni (GLPG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):